{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:02Z","timestamp":1793126042377,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107653","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:58:23Z","timestamp":1788155903000},"page":"107653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The top-down Finite Time Pharmacokinetic (FTPK) models vis-a-vis the bottom-up PBPK models in early drug development"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-0552","authenticated-orcid":false,"given":"Panos","family":"Macheras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0827-9729","authenticated-orcid":false,"given":"Nikos","family":"Alimpertis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4757-324X","authenticated-orcid":false,"given":"Athanasios A.","family":"Tsekouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107653_bib0001","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s11095-023-03578-x","article-title":"Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption","volume":"40","author":"Alimpertis","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11095-024-03653-x","article-title":"IVIVC Revised","volume":"41","author":"Alimpertis","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0003","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0004","series-title":"Advances in Pharmacokinetics and Pharmacodynamics. AAPS Introductions in the Pharmaceutical Sciences","first-page":"3","article-title":"Current Status in PBPK Modeling","volume":"9","author":"Asaumi","year":"2023"},{"key":"10.1016\/j.ejps.2026.107653_bib0005","first-page":"423","article-title":"The solution of a system of differential equations occurring in the theory of radioactive transformations","volume":"15","author":"Bateman","year":"1910","journal-title":"Proc. Cambridge Philos. Soc. Math. Phys. Sci."},{"key":"10.1016\/j.ejps.2026.107653_bib0006","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3109\/03639045.2013.819880","article-title":"A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men","volume":"40","author":"Chae","year":"2013","journal-title":"Drug Developm. Ind. Pharmacy."},{"key":"10.1016\/j.ejps.2026.107653_bib0007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s11095-021-03078-w","article-title":"Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations","volume":"38","author":"Chryssafidis","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0008","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11095-022-03230-0","article-title":"Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models","volume":"39","author":"Chryssafidis","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1099-081X(199603)17:2<135::AID-BDD947>3.0.CO;2-K","article-title":"The lack effect of food on the bioavailability of nefazodone tablets","volume":"17","author":"Dockens","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2026.107653_bib0010","unstructured":"Food and Drug Administration, 2021. M9 Biopharmaceutics Classification System-Based Biowaivers: Guidance for Industry."},{"key":"10.1016\/j.ejps.2026.107653_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14366\/usg.15020","article-title":"Altered Doppler flow patterns in cirrhosis patients: an overview","volume":"35","author":"Iranpour","year":"2016","journal-title":"Ultrasonography"},{"key":"10.1016\/j.ejps.2026.107653_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107485","article-title":"The top-down Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models open a new avenue for early drug development","volume":"220","author":"Kalantzi","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107653_bib0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/pharmaceutics17111413","article-title":"The Evolution and Future Directions of PBPK Modeling in FDA Regulatory Review","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107653_bib0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11095-019-2633-4","article-title":"On an unphysical hypothesis of Bateman equation and its implications for pharmacokinetics","volume":"36","author":"Macheras","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11095-020-02894-w","article-title":"Revising pharmacokinetics of oral drug absorption: I models based on biopharmaceutical\/physiological and finite absorption time concepts","volume":"37","author":"Macheras","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106265","article-title":"Columbus' egg: oral drugs are absorbed in finite time","volume":"176","author":"Macheras","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107653_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10928-022-09832-w","article-title":"The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics","volume":"50","author":"Macheras","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2026.107653_bib0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s11095-025-03878-4","article-title":"The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology","volume":"42","author":"Macheras","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1023\/A:1018947113238","article-title":"Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model","volume":"10","author":"Oh","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1208\/s12248-020-00548-8","article-title":"Understanding mechanisms of food effect and developing reliable PBPK models using a middle-out approach","volume":"23","author":"Pepin","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2026.107653_bib0023","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1023\/A:1015892621261","article-title":"Predicting fraction dose absorbed in humans using a macroscopic mass balance approach","volume":"8","author":"Sinko","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107653_bib0024","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5599\/admet.923","article-title":"Lost in modelling and simulation?","volume":"9","author":"Sugano","year":"2021","journal-title":"ADMET. DMPK."},{"key":"10.1016\/j.ejps.2026.107653_bib0025","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/pharmaceutics16111435","article-title":"FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes","volume":"16","author":"Toulitsis","year":"2024","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:54:34Z","timestamp":1793123674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"alternative-id":["S0928098726002277"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107653","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The top-down Finite Time Pharmacokinetic (FTPK) models vis-a-vis the bottom-up PBPK models in early drug development","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107653"}}